Design of self-emulsifying oral delivery systems for semaglutide: reverse micelles versus hydrophobic ion pairs.
Drug Deliv Transl Res · 2025
Last updated 2026-05-28This study tested two methods—reverse micelles (RM) and hydrophobic ion pairs (HIP)—to deliver semaglutide, a GLP-1 drug, in oral form. Formulas with RM increased semaglutide’s solubility and absorption by 4.2 times compared to HIP, while maintaining droplet sizes between 50 and 300 nanometers and showing no major harm to cells at tested doses. Both methods improved semaglutide’s ability to pass through cell layers by at least 2 times.
AI summary of the abstract below.
| Journal | Drug Deliv Transl Res, 2025 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 3.58 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
It was the aim of this study to evaluate the potential of reverse micelles (RM) and hydrophobic ion pairs (HIP) for incorporation of semaglutide into self-emulsifying oral drug delivery systems. Reverse micelles loaded with semaglutide were formed with a cationic (ethyl lauroyl arginate, ELA) and an anionic surfactant (docusate, DOC), whereas HIP were formed between semaglutide and ELA. Maximum solubility of the peptide and the rate of dissolution was evaluated in various lipophilic phases (glycerol monocaprylocaprate:caprylic acid 1:4 (m/m), glycerol monolinoleate:caprylic acid 1:4 (m/m) and glycerol monocaprylocaprate:glycerol monolinoleate 1:4 (m/m)). Self-emulsifying drug delivery systems (SEDDS) loaded with RM and HIP were characterized regarding size distribution, zeta potential, cytocompatibility and Caco-2 permeability. Droplet sizes between 50 and 300 nm with polydispersity index (PDI) around 0.3 and zeta potentials between - 45 mV (RM) and 36 mV (RM) were obtained. RM provided an almost 2-fold higher lipophilicity of semaglutide than HIP resulting in a 4.2-fold higher payload of SEDDS compared to HIP. SEDDS containing RM or HIP showed high cytocompatibilities with a cell survival above 75% for concentrations up to 0.1% on Caco-2 cells and acceptable hemolytic activity. Permeation studies across Caco-2 monolayer revealed an at least 2-fold increase in permeability of semaglutide for the developed formulations.
Verbatim abstract via PubMed 39427069 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.